Switch theme
Sign up to access all valuation multiples
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
1993
5.6K+
LTM Revenue $433M
LTM EBITDA $124M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Syngene International has a last 12-month revenue of $433M and a last 12-month EBITDA of $124M.
In the most recent fiscal year, Syngene International achieved revenue of $391M and an EBITDA of $127M.
Syngene International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Syngene International valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $358M | $391M | XXX | XXX | XXX |
| Gross Profit | $204M | $258M | XXX | XXX | XXX |
| Gross Margin | 57% | 66% | XXX | XXX | XXX |
| EBITDA | $116M | $127M | XXX | XXX | XXX |
| EBITDA Margin | 32% | 32% | XXX | XXX | XXX |
| Net Profit | $46.0M | $53.9M | XXX | XXX | XXX |
| Net Margin | 13% | 14% | XXX | XXX | XXX |
| Net Debt | $61.4M | $56.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Syngene International's stock price is INR 702 (or $8).
Syngene International has current market cap of INR 282B (or $3.3B), and EV of INR 278B (or $3.2B).
See Syngene International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.3B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Syngene International has market cap of $3.3B and EV of $3.2B.
Syngene International's trades at 7.4x LTM EV/Revenue multiple, and 25.9x LTM EBITDA.
Analysts estimate Syngene International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Syngene International and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 25.9x | XXX | XXX | XXX |
| P/E | 56.7x | XXX | XXX | XXX |
| P/E/Growth | 2.5x | XXX | XXX | XXX |
| EV/FCF | 93.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSyngene International's NTM/LTM revenue growth is 15%
Syngene International's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $37K for the same period.
Over next 12 months, Syngene International's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Syngene International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Syngene International and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 44% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $37K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Syngene International acquired XXX companies to date.
Last acquisition by Syngene International was XXXXXXXX, XXXXX XXXXX XXXXXX . Syngene International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Syngene International founded? | Syngene International was founded in 1993. |
| Where is Syngene International headquartered? | Syngene International is headquartered in India. |
| How many employees does Syngene International have? | As of today, Syngene International has 5.6K+ employees. |
| Who is the CEO of Syngene International? | Syngene International's CEO is Mr. Jonathan Hunt. |
| Is Syngene International publicy listed? | Yes, Syngene International is a public company listed on BOM. |
| What is the stock symbol of Syngene International? | Syngene International trades under 539268 ticker. |
| When did Syngene International go public? | Syngene International went public in 2015. |
| Who are competitors of Syngene International? | Similar companies to Syngene International include e.g. Jubilant Pharmova, Biocon, Dishman Carbogen Amics, Suven Pharma. |
| What is the current market cap of Syngene International? | Syngene International's current market cap is $3.3B |
| What is the current revenue of Syngene International? | Syngene International's last 12-month revenue is $433M. |
| What is the current EBITDA of Syngene International? | Syngene International's last 12-month EBITDA is $124M. |
| What is the current EV/Revenue multiple of Syngene International? | Current revenue multiple of Syngene International is 7.4x. |
| What is the current EV/EBITDA multiple of Syngene International? | Current EBITDA multiple of Syngene International is 25.9x. |
| What is the current revenue growth of Syngene International? | Syngene International revenue growth between 2023 and 2024 was 9%. |
| Is Syngene International profitable? | Yes, Syngene International is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
